Following several recently published studies, the CHMP concluded that a clinically significant interaction exists between clopidogrel and PPIs. The studies examined the clinical outcomes of patients taking clopidogrel and suggested that a significant interaction occurs between clopidogrel and PPIs, making clopidogrel less effective.
This interaction has important implications. PPIs are often prescribed concomitantly to offer gastroprotection as clopidogrel is associated with gastrointestinal symptoms.
The CHMP advice for healthcare professionals is that all patients currently receiving the two drugs should be reviewed at their next appointment; PPIs should only be prescribed strictly within their licensed indications and that prescribers should check that patients prescribed clopidogrel are not buying over-the-counter omeprazole.
Further information: European Medicines Agency Public statement